Immuneering (NASDAQ:IMRX – Get Free Report) and Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Immuneering and Amicus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immuneering | N/A | -73.49% | -65.01% |
| Amicus Therapeutics | -2.35% | 6.95% | 1.75% |
Institutional & Insider Ownership
67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immuneering | N/A | N/A | -$61.04 million | ($1.78) | -3.00 |
| Amicus Therapeutics | $528.29 million | 8.33 | -$56.11 million | ($0.04) | -356.75 |
Amicus Therapeutics has higher revenue and earnings than Immuneering. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Immuneering and Amicus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immuneering | 1 | 0 | 5 | 1 | 2.86 |
| Amicus Therapeutics | 1 | 8 | 4 | 1 | 2.36 |
Immuneering currently has a consensus target price of $16.50, suggesting a potential upside of 208.99%. Amicus Therapeutics has a consensus target price of $15.55, suggesting a potential upside of 8.97%. Given Immuneering’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Immuneering is more favorable than Amicus Therapeutics.
Risk & Volatility
Immuneering has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
Summary
Immuneering beats Amicus Therapeutics on 8 of the 13 factors compared between the two stocks.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
